TAKE-HOME MESSAGE High-flow nasal cannula and conventional oxygen therapy demonstrate similar results in the treatment of acute respiratory failure in regard to rates of respiratory support escalation, intubation, mortality, and ICU transfer, although it may decrease the need for escalation of respiratory support and intubation among patients with acute respiratory failure who are undergoing treatment for greater than or equal to 24 hours.
Results
Results of included trials. Authors included 4 studies with 703 patients from an initial 1,030 citations retrieved from literature searches. Two studies evaluated high-flow nasal cannula greater than or equal to 24 hours, 2,3 and 2 studies evaluated high-flow nasal cannula less than 24 hours. 4, 5 The setting was emergency department (ED) for 2 studies and ICU for the other 2 studies. Criteria for acute respiratory failure varied among included studies. All studies reported rate of escalation for respiratory support, although the escalation strategies differed. Highflow nasal cannula did not demonstrate a difference compared with conventional oxygen therapy in the random-effects model, but subgroup analysis demonstrated a 29% decrease in escalation of respiratory support for patients treated with high-flow nasal cannula greater than or equal to 24 hours (Table) 
STUDY SELECTION
Two authors included randomized controlled trials comparing highflow nasal cannula and conventional oxygen therapy for the treatment of adult acute respiratory failure. Conventional oxygen therapy included oxygen provided by nasal prongs, face mask, or Venturi mask. The 2 authors resolved disagreements through consensus or discussion with a third author.
DATA EXTRACTION AND SYNTHESIS
Two investigators independently extracted data from included studies. Authors expressed rate of escalation in respiratory care and intubation as risk ratios with 95% confidence intervals. They assessed study quality with the Jadad score, risk of bias according to the Cochrane Handbook, and the conventional oxygen therapy and high-flow nasal cannula groups. Funnel plot revealed no publication bias. Studies were at low risk for biases of selection, performance, reporting, and other, with the exception of performance and detection bias because blinding of participants and outcome assessment was not possible.
Commentary
Acute respiratory failure can be a life-threatening complication of many disease processes. The primary treatment is oxygenation, usually by nasal cannula or face mask. However, these modalities have limited maximal flow rate, minimizing the FiO 2 . 4, 6 High-flow nasal cannula is a newer device that delivers humidified and heated supplemental oxygen (up to FiO 2 1.0) through the nares, with a maximal flow rate of 60 L/min. 6 This device provides minimal positive airway pressure and flushes anatomic dead space, improving oxygenation and reducing work of breathing. [7] [8] [9] High-flow nasal cannula may improve the respiratory status of patients in acute respiratory failure, although the literature remains inconclusive about its benefits.
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This meta-analysis sought to compare high-flow nasal cannula with conventional oxygen therapy in acute respiratory failure.
It examined 4 randomized controlled trials including 703 patients. Overall, high-flow nasal cannula and conventional oxygen therapy did not demonstrate differences in rates of escalation for respiratory support, intubation, mortality, or ICU transfer for patients with acute respiratory failure. Subgroup analysis demonstrated that high-flow nasal cannula greater than or equal to 24 hours may decrease rates of respiratory support escalation and intubation compared with conventional oxygen therapy. However, optimal duration of highflow nasal cannula in acute respiratory failure remains unclear.
Limitations of this meta-analysis include significant heterogeneity among the included studies in regard to criteria defining acute respiratory failure, study setting, patient selection, illness and acute respiratory failure severity, highflow nasal cannula starting flow rate (thus affecting positive end-expiratory pressure), criteria for escalation of respiratory support, and durations of high-flow nasal cannula (ranging from 2 to 24 hours). The effect of these sources of heterogeneity is unclear. Only one study 5 yielded a point estimate suggesting no benefit in regard to decreased risk of intubation with high-flow nasal cannula, and that study enrolled immunocompromised ICU patients. Further analysis of less critically ill patients more representative of an ED patient population may yield different results. Similarly, high-flow nasal cannula may have different effects among patients with acute respiratory failure complicated by hypoxia versus acute respiratory failure complicated by hypercapnia. The lack of these and other subgroup analyses is likely due in part to the small number of included studies and sample sizes and is an important limitation of this meta-analysis. As a result, it is unclear whether these results failed to demonstrate a difference between high-flow nasal cannula and conventional oxygen therapy as opposed to demonstrating no difference.
This meta-analysis demonstrates that high-flow nasal cannula yields outcomes similar to those of conventional oxygen therapy among patients with acute respiratory failure. Larger studies with similar definitions of acute respiratory failure, high-flow nasal cannula flow rate, and criteria for respiratory support escalation are necessary, as well as comparisons of high-flow nasal cannula versus other forms of noninvasive positive-pressure ventilation. 
